Brought to you by 
Amgen acquires Tularik in $1.3bn stock swap
Mar 2004
Executive Summary
In a tax-free stock swap worth about $1.3bn, Amgen has agreed to acquire the remaining 78.7% (or 52.7mm shares) of Tularik (develops drugs that act through gene expression regulation) that it does not already own.
Deal Industry
-
Biotechnology
-
Drug Discovery Tools
- Genomics-Proteomics
-
Drug Discovery Tools
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Acquisition
- Intra-Biotech Deal
- Payment Includes Stock
- Partial Acquisition
Already a Strategic Transactions subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Amgen acquires Tularik in $1.3bn stock swap
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice